Objective: This study evaluated the performance of a flow cytometry system (LC-1000) in screening cervical precancerous lesions at routine health checkups. Study design: In total, 928 health examinees were enrolled at 16 health promotion centers in 13 Korean cities between 2016 and 2017. All participants underwent liquid-based cervical cytology and flow cytometry testing to determine the cell proliferation index (CPIx). Results: The positivity rate of the LC-1000 system increased with the severity of the cervical cytology findings (p for trend < 0.001). When low-grade squamous intraepithelial lesion (LSIL) or higher (including LSIL, high-grade squamous intraepithelial lesion [HSIL], and atypical squamous cells without excluding HSIL [ASC-H]) was defined as gold-standard positivity, the sensitivity, specificity, PPV, and NPV of LC-1000 were 75.3% (95% confidence interval [CI], 66.8–83.7), 58.5% (95% CI, 55.2–61.9), 18.1% (95% CI, 14.5–21.8), and 95.1% [95% CI, 93.2–97.0], respectively. The median CPIx increased significantly from normal cytology to HSIL (p < 0.001). The median CPIx was higher in high-risk human papillomavirus (HR-HPV)-positive cases than in HR-HPV-negative cases (0.23 vs. 0.17, p < 0.001), while it did not differ between HR-HPV-positive and HR-HPV-negative cases with normal cytology findings (0.16 vs. 0.16, p = 0.700). Conclusion: The LC-1000 system is potentially useful for screening cervical precancer and cancer, especially when excluding normal or ASC of undetermined significance cases in routinely screened populations.

Keywords:
Flow cytometry, Cervical cancer screening, Liquid-based cytology
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2.
Soler ME, Gaffikin L, Blumenthal PD: Cervical cancer screening in developing countries. Prim Care Update Ob Gyns 2000; 7: 118–123.
3.
Monsonego J, Autillo-Touati A, Bergeron C, Dachez R, Liaras J, Saurel J, et al: Liquid-based cytology for primary cervical cancer screening: a multi-centre study. Br J Cancer 2001; 84: 360–366.
4.
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137: 516–452.
5.
Kimmig R, Kapsner T, Spelsberg H, Untch M, Hepp H: DNA cell-cycle analysis of cervical cancer by flow cytometry using simultaneous cytokeratin labelling for identification of tumour cells. J Cancer Res Clin Oncol 1995; 121: 107–114.
6.
Lorenzato M, Bory JP, Cucherousset J, Nou JM, Bouttens D, Thil C, et al: Usefulness of DNA ploidy measurement on liquid-based smears showing conflicting results between cytology and high-risk human papillomavirus typing. Am J Clin Pathol 2002; 118: 708–713.
7.
Mishra S, Awasthi NP, Husain N, Anand A, Pradeep Y, Ansari R, et al: Flow cytometric analysis of DNA ploidy in liquid based cytology for cervical pre-cancer and cancer. Asian Pac J Cancer Prev 2017; 18: 1595–1601.
8.
Morisaki H, Abe S, Ebi R, Morita M, Oguro M, Tajima K, et al: A novel method for DNA cytometry of exfoliated cells. Cytometry Res 2014; 24: 41–52.
9.
Han X, Ping B, Morita M, Ebi R, Inoue J, Tanaka Y, et al: A novel highly sensitive and specific flow cytometry system for cervical cancer screening. Gynecol Oncol 2015; 139: 52–58.
10.
Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114–2119.
11.
Baba AI, Catoi C: Comparative Oncology. The Publishing House of the Romanian Academy, 2007.
12.
Shirasuna K, Ebi R, Abe S: Cell analysis method, cell analyzer and sample screening method. Eur Patent Appl 2015; 1–32.
13.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100: 57–70.
14.
Bollmann R, Bollmann M, Henson DE, Bodo M: DNA cytometry confirms the utility of the Bethesda system for the classification of Papanicolaou smears. Cancer 2001; 93: 222–228.
15.
Tong H, Shen R, Wang Z, Kan Y, Wang Y, Li F, et al: DNA ploidy cytometry testing for cervical cancer screening in China (DNACIC Trial): a prospective randomized, controlled trial. Clin Cancer Res 2009; 15: 6438–6445.
16.
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS: Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123–137.
17.
Carcopino X, Bolger N, Henry M, Mancini J, Boubli L, Olive D, et al: Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology. J Med Virol 2011; 83: 637–643.
18.
Burd EM: Updated guidelines for cervical cancer screening: Clin Microbiol Newsl 2014; 36: 95–103.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.